MiMedx Group Inc Cash Flow Conversion Efficiency
MiMedx Group Inc cash flow conversion efficiency. Based on the latest financial reports, MiMedx Group Inc (MDXG) has a cash flow conversion efficiency ratio of 0.123x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($29.33 Million) by net assets ($238.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MiMedx Group Inc market cap and net worth for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of MiMedx Group Inc (2006–2024)
Cash flow conversion efficiency of MiMedx Group Inc from 2006 to 2024. This chart illustrates how MiMedx Group Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MiMedx Group Inc stock quote for real-time trading data and today's change.
MiMedx Group Inc Cash Flow Conversion Ratio Explained
MiMedx Group Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MiMedx Group Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MiMedx Group Inc ranked by their cash flow conversion efficiency. Review how much free cash does MiMedx Group Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Konka Group Co Ltd
SHE:000016
|
0.068x |
|
SeaBird Exploration Plc
OL:SBX
|
0.148x |
|
Shenzhen Shengxunda Technology Co Ltd Class A
SHE:300518
|
0.020x |
|
Achieve Life Sciences Inc
F:SP4P
|
-0.649x |
|
Geron Corporation
NASDAQ:GERN
|
-0.072x |
|
Zhejiang Langdi Group Co Ltd
SHG:603726
|
0.042x |
|
CJ CGV
KO:079160
|
0.005x |
|
Nanjing Quanxin Cable Technology Co Ltd
SHE:300447
|
0.081x |
Annual Cash Flow Conversion Efficiency for MiMedx Group Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of MiMedx Group Inc from 2006 to 2024. Also see MDXG total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $193.11 Million | $66.20 Million | 0.343x | +82.72% |
| 2023-12-31 | $142.72 Million | $26.77 Million | 0.188x | +178.12% |
| 2022-12-31 | $74.51 Million | $-17.89 Million | -0.240x | -1021.73% |
| 2021-12-31 | $92.58 Million | $-1.98 Million | -0.021x | +95.03% |
| 2020-12-31 | $91.42 Million | $-39.41 Million | -0.431x | -159.80% |
| 2019-12-31 | $49.66 Million | $35.80 Million | 0.721x | 0.00% |
| 2018-12-31 | $49.66 Million | $35.80 Million | 0.721x | -15.47% |
| 2017-12-31 | $73.80 Million | $62.94 Million | 0.853x | +339.18% |
| 2016-12-31 | $133.00 Million | $25.83 Million | 0.194x | +11.51% |
| 2015-12-31 | $107.99 Million | $18.81 Million | 0.174x | -7.41% |
| 2014-12-31 | $89.33 Million | $16.80 Million | 0.188x | +4947.15% |
| 2013-12-31 | $73.57 Million | $-285.48K | -0.004x | +97.71% |
| 2012-12-31 | $20.01 Million | $-3.38 Million | -0.169x | +69.80% |
| 2011-12-31 | $11.90 Million | $-6.66 Million | -0.560x | +58.10% |
| 2010-12-31 | $6.10 Million | $-8.16 Million | -1.337x | +5.10% |
| 2009-12-31 | $6.07 Million | $-8.56 Million | -1.409x | -146.44% |
| 2008-12-31 | $14.23 Million | $-8.14 Million | -0.572x | -186.00% |
| 2007-12-31 | $-35.60K | $-23.67K | 0.665x | +109.17% |
| 2006-12-31 | $3.26K | $-23.65K | -7.250x | -- |
About MiMedx Group Inc
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines,… Read more